Coles Group Q3 Sales Rise Driven by Supermarkets and E-Commerce Growth 
Samsung Appoints New TV Business Head Amid Rising Competition from Chinese Rivals 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
NAB First-Half Earnings Miss Forecasts Amid Rising Global Risks 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Berkshire Hathaway Meeting Sees Shift as Greg Abel Steps Into Leadership Spotlight 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
Middle East Conflict Impacts Australia and New Zealand Businesses 
Supreme Court Asked to Reinstate Mail-Order Access to Abortion Pill Mifepristone 
Spirit Airlines Shuts Down Flights, Issues Refunds After Financial Collapse 
Anthropic Secures $1.5B AI Venture Backed by Wall Street Giants, Shaking Software Sector 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
Palantir Reports Record Growth, Raises 2026 Revenue Outlook Above Expectations 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
LAKE FOREST, Ill., May 03, 2018 -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will release first-quarter 2018 financial results on Thursday, May 10, 2018, before the open of markets. Following the announcement, the Company will host a conference call beginning at 8:30 a.m. ET to discuss its results.
Participants can access the live webcast from the Investor Relations section of Depomed's website at http://www.depomed.com. Please access the website 15 minutes prior to the start of the call to download and install any necessary audio software. An archived webcast replay will be available on the Company's website for three months.
Audio Conference Call:
| U.S. Dial-in Number: | 1-877-326-2337 |
| International Dial-in Number: | 1-631-456-4258 |
| Conference ID: | 1328285277 |
An archived webcast replay will be available on the Company's website for three months.
About Depomed
Depomed is a leading specialty pharmaceutical company committed to putting the patient first in everything it does. Depomed is focused on enhancing the lives of patients, families, physicians, providers and payors through the commercialization of products in the areas of pain and neurology, and in the development of drugs in areas of unmet medical need. Depomed currently markets three medicines focused on neuropathic pain and migraine through its Neurology and Pain businesses and its emerging Orphan Specialty Business is focused on orphan drug indications and areas of unmet medical need. To learn more about Depomed, visit www.depomed.com.
INVESTOR AND MEDIA CONTACTS:
John B. Thomas
SVP, Investor Relations and Corporate Communications
[email protected]
